Docetaxel and Cisplatin (DP) Regimen for Solid Tumors-Reference-Cited by-同舟云学术

Docetaxel and Cisplatin (DP) Regimen for Solid Tumors

Published:2006-11 Issue:11 Volume:41 Page:1032-1042
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Franklin Kaitlyn¹,Solimando Dominic A.²,Waddell J. Aubrey³

Affiliation:

1. Jamestown Community College, Jamestown, NY.

2. Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203

3. University of Tennessee College of Pharmacy, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804

Abstract

The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pharmacology,Pharmacy

Link

http://journals.sagepub.com/doi/pdf/10.1310/hpj4111-1032

Reference75 articles.

1. Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines

2. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer

3. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial

4. Docetaxel and Cisplatin as Primary Chemotherapy for Treatment of Locally Advanced Breast Cancers

5. Docetaxel–cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer